008490.KS
Suheung Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 21,350.00
−0.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 765.9B | 722.3B | 653.3B | 594.6B | 635.0B |
| Cost of Revenue | 631.3B | 599.0B | 550.0B | 495.5B | 497.7B |
| Gross Profit | 134.6B | 123.3B | 103.2B | 99.0B | 137.3B |
| Operating Expenses | |||||
| R&D Expense | 9.2B | 9.5B | 7.9B | 7.0B | 7.4B |
| SG&A Expense | 44.5B | 35.9B | 27.0B | 26.2B | 41.5B |
| General & Admin Expense | 3.3B | 3.9B | 3.9B | 3.4B | 3.1B |
| Selling & Marketing Expense | 32.6B | 32.0B | 23.1B | 22.9B | 38.4B |
| Other Expenses | 25.9B | 27.2B | 34.6B | 22.8B | 26.4B |
| Total Operating Expenses | 77.0B | 72.6B | 69.4B | 56.0B | 75.3B |
| Cost and Expenses | 703.8B | 672.1B | 619.4B | 551.6B | 573.0B |
| Operating Income (EBIT) | 62.3B | 50.7B | 33.8B | 43.0B | 62.0B |
| Non-Operating | |||||
| Interest Income | 2.9B | 2.8B | 2.7B | 1.7B | 772.6M |
| Interest Expense | 16.6B | 17.6B | 21.0B | 19.7B | 11.2B |
| Net Interest Income | (13.7B) | (14.8B) | (18.3B) | (18.0B) | (10.4B) |
| Other Non-Op Income/Expense | (1.0B) | 3.1B | (2.6B) | (29.0B) | (10.0B) |
| Non-Operating Income (excl Interest) | (9.4B) | (20.7B) | (18.4B) | 2.3B | (1.2B) |
| EBT (Pre-Tax Income) | 61.2B | 53.8B | 31.2B | 14.0B | 51.9B |
| Income Tax Expense | 13.6B | 6.6B | 9.7B | 5.1B | 11.3B |
| Bottom Line | |||||
| Net Income | 39.1B | 43.5B | 18.3B | 6.1B | 34.0B |
| Earnings from Cont. Ops | 47.7B | 47.1B | 21.6B | 15.9B | 40.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 39.1B | 43.5B | 18.3B | 6.1B | 34.0B |
| Per Share | |||||
| Basic EPS | ₩3,517 | ₩3,911 | ₩1,643 | ₩550 | ₩3,056 |
| Diluted EPS | ₩3,517 | ₩3,911 | ₩1,643 | ₩550 | ₩3,056 |
| Revenue Per Share | ₩68,777 | ₩62,435 | ₩58,752 | ₩53,473 | ₩57,106 |
| Shares | |||||
| Basic Shares Outstanding | 11.1M | 11.6M | 11.1M | 11.1M | 11.1M |
| Diluted Shares Outstanding | 11.1M | 11.6M | 11.1M | 11.1M | 11.1M |
| Profitability Metrics | |||||
| EBITDA | 78.7B | 91.2B | 73.5B | 77.0B | 98.6B |
| D&A | 41.7B | 40.5B | 39.9B | 36.3B | 35.4B |
| EBIT | 36.9B | 50.7B | 33.6B | 40.7B | 63.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026